We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug News
Trending
Commercial Operations
GMPs
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Device News
Trending
Commercial Operations
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Books
FDAnews Books Library
Drug Books
Device Books
Training/Events
Webinar Training Pass
Events
Webinar Recordings
Resources
Form 483s Database
FDA Approved Drugs
CenterWatch
WCG Clinical
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Thuy Thanh Nguyen
Thuy Thanh Nguyen
Products
PRODUCTS
Janssen Vaccines Corp.
Santos E. Camara
,
Thuy Thanh Nguyen
, and
Melissa Ray
Price:
$117.00
View
AstraZeneca AB
Thuy Thanh Nguyen
and
Wendy G. Tan
Price:
$117.00
View
Samsung Biologics
Ralph M. Bernstein
,
Alicia Mozzachio
,
Riley Myers
, and
Thuy Thanh Nguyen
Price:
$117.00
View
Daewoong Pharmaceutical Co., Ltd.
Ennan Guan
,
Davinna Ligons
,
Viviana Matta
,
Alicia Mozzachio
, and
Thuy Thanh Nguyen
Price:
$117.00
View
Boehringer Ingelheim Pharma GmbH and Co. KG (BIB)
Thuy Thanh Nguyen
,
Zhihao Peter Qiu
,
Wayne Seifert
, and
Qing Joanna Zhou
Price:
$117.00
View
GlaxoSmithKline
M Gutierrez Lugo
,
Richard A. Lyght
,
F Namuswe
,
Thuy Thanh Nguyen
,
Zhihao Peter Qiu
, and
Michael R. Shanks
Price:
$117.00
View
Prism Medical USA, Inc.
Steven D. Kehoe
and
Thuy Thanh Nguyen
Price:
$117.00
View
Home Medical Supply of Poplar Bluff, Inc.
Thuy Thanh Nguyen
Price:
$117.00
View
Healthcare Equipment & Supply
Thuy Thanh Nguyen
Price:
$117.00
View
Upcoming Events
21
Oct
MAGI@home Clinical Research Conference 2024
Featured Products
From QSR to QMSR: Meeting FDA’s New Requirements
FDA Oversight of Laboratory-Developed Tests — The Impact of the Final Rule
Featured Stories
Risk of 10 Obesity-Driven Cancers Reduced by GLP-1s, Study Says
Three Device Areas Added to CDRH’s Device-Advancing TAP Program
Third Alzheimer’s Drug Gets FDA Approval, Just as Diagnostic Criteria Expand
Draft Guidance Covers Using URRAs in Combo Product Applications
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More
